OBJECTIVES: The objective of this study is to determine the direct costs of the use of PPI for the treatment of erosive form (ЕF) and non-erosive form (NEF) of GERD in patients of working age in Ukraine.  METHODS: Сost analysis for PPIs was conducted for a minimum course of treatment of GERD in one patient: NEF – 4 weeks, ЕF – 8 weeks. Daily doses of preparations were used in calculations: omeprazole, rabeprazole - 20 mg; pantoprazole, esomeprazole - 40 mg; lansoprazole – 30 mg, (as recommended by the Ukrainian unified clinical protocol “Gastroesophageal Reflux Disease”, 2013). When calculating the direct costs, the cost of PPIs was only taken into account. Prices of drugs were taken from the Morion information system “Drugs” (November 2014). The rate of hryvnia to dollar (USD) as of 28.11.14 was 14.96:1. To determine the range of costs for the use of PPIs, their trade names with the minimum and maximum costs of treatment of the disease in one patient were determined. RESULTS: The range of costs for the use of PPIs for the treatment of GERD is quite wide in Ukraine: NEF of GERD:  omeprazole – 0.99 – 15.18 $, pantoprazole – 5.18 – 47.91$, lansoprazole – 3.18 – 12.76 $, rabeprazole – 3.18 – 96.46 $, esomeprazole 13.70 – 56.17 $; ЕF of GERD:  omeprazole -  1.98 – 30.36 $, pantoprazole – 10.37 -95.83 $, lansoprazole – 6.36 – 25.53 $, rabeprazole – 6.36– 192.93 $, esomeprazole 27.40 – 112.34 $.  CONCLUSIONS: The cost of use of PPIs only for the minimal treatment of GERD can be quite high. Therefore, when choosing the PPI for treatment of the disease it is advisable to use the results of pharmacoeconomic studies that will optimize the costs of the payer for the treatment of GERD.